IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 381 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $349,272 | +13.5% | 7,700 | +2.7% | 0.01% | +25.0% |
| Q2 2023 | $307,725 | +14.8% | 7,500 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $268,050 | -5.4% | 7,500 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $283,275 | -14.7% | 7,500 | 0.0% | 0.00% | -33.3% |
| Q3 2022 | $332,000 | +21.2% | 7,500 | +1.4% | 0.01% | +50.0% |
| Q2 2022 | $274,000 | 0.0% | 7,400 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $274,000 | -64.6% | 7,400 | -70.9% | 0.00% | -60.0% |
| Q4 2021 | $773,000 | -9.0% | 25,409 | +0.4% | 0.01% | -9.1% |
| Q3 2021 | $849,000 | -20.3% | 25,309 | -5.2% | 0.01% | -21.4% |
| Q2 2021 | $1,065,000 | -5.7% | 26,709 | +6.4% | 0.01% | -12.5% |
| Q1 2021 | $1,129,000 | -23.8% | 25,109 | -4.2% | 0.02% | -23.8% |
| Q4 2020 | $1,481,000 | +24.8% | 26,209 | +4.8% | 0.02% | +5.0% |
| Q3 2020 | $1,187,000 | -19.1% | 25,009 | +0.4% | 0.02% | -25.9% |
| Q2 2020 | $1,468,000 | +27.2% | 24,909 | +2.0% | 0.03% | +8.0% |
| Q1 2020 | $1,154,000 | -21.7% | 24,409 | 0.0% | 0.02% | -3.8% |
| Q4 2019 | $1,474,000 | +1.2% | 24,409 | +0.4% | 0.03% | -7.1% |
| Q3 2019 | $1,457,000 | -5.6% | 24,309 | +1.2% | 0.03% | -6.7% |
| Q2 2019 | $1,543,000 | -19.4% | 24,009 | +1.8% | 0.03% | -21.1% |
| Q1 2019 | $1,914,000 | +51.9% | 23,580 | +1.2% | 0.04% | +35.7% |
| Q4 2018 | $1,260,000 | +5.4% | 23,300 | +0.4% | 0.03% | +21.7% |
| Q3 2018 | $1,196,000 | +24.2% | 23,200 | +0.4% | 0.02% | +15.0% |
| Q2 2018 | $963,000 | -5.0% | 23,100 | +0.4% | 0.02% | -9.1% |
| Q1 2018 | $1,014,000 | -12.4% | 23,000 | 0.0% | 0.02% | -8.3% |
| Q4 2017 | $1,157,000 | +1.0% | 23,000 | +1.8% | 0.02% | -7.7% |
| Q3 2017 | $1,145,000 | -0.3% | 22,600 | 0.0% | 0.03% | -3.7% |
| Q2 2017 | $1,149,000 | +30.0% | 22,600 | +2.7% | 0.03% | +28.6% |
| Q1 2017 | $884,000 | -15.6% | 22,000 | +0.5% | 0.02% | -19.2% |
| Q4 2016 | $1,048,000 | +30.5% | 21,900 | 0.0% | 0.03% | +23.8% |
| Q3 2016 | $803,000 | +57.5% | 21,900 | 0.0% | 0.02% | +50.0% |
| Q2 2016 | $510,000 | -41.1% | 21,900 | +2.3% | 0.01% | -39.1% |
| Q1 2016 | $866,000 | -34.6% | 21,400 | 0.0% | 0.02% | -36.1% |
| Q4 2015 | $1,325,000 | – | 21,400 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |